News & Analysis as of

Antitrust Litigation › Endo Pharmaceuticals

WilmerHale

The Interplay: Key Decisions at the Intersection of Antitrust & Life Sciences - September 2023

WilmerHale on

This marks the first issue of WilmerHale’s The Interplay: Key Decisions at the Intersection of Antitrust & Life Sciences, a monthly bulletin that will highlight developments in the antitrust and life sciences space. We will...more

Patterson Belknap Webb & Tyler LLP

FTC Launches First-Ever Attack on “No-AG Commitment” Pay-for-Delay Settlements

Patterson Belknap Webb & Tyler LLP on

Today the FTC filed a complaint in the U.S. District Court for the Eastern District of Pennsylvania against Endo Pharmaceuticals for entering into “pay-for-delay” agreements with two different generic manufacturers that...more

Patterson Belknap Webb & Tyler LLP

Northern District of California Upholds Assignment of Antitrust Claims to Indirect Purchasers

Patterson Belknap Webb & Tyler LLP on

Portions of a reverse payment suit against Endo Pharmaceuticals and others were recently dismissed by Judge William H. Orrick of the Northern District of California. The case was brought by plaintiffs who allege that a...more

3 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide